Skip to main content
. 2023 Feb 20;29(11):2066–2074. doi: 10.1158/1078-0432.CCR-22-2765

Figure 3.

Figure 3. Forest plot of OS in the bTMB-high and bTMB-low subgroups by bTMB cutoff for durvalumab monotherapy versus SoC (A) and for durvalumab plus tremelimumab versus SoC (B) and PFS in the bTMB-high and bTMB-low subgroups by bTMB cutoff for durvalumab versus SoC (C) and for durvalumab plus tremelimumab versus SoC (D) in EAGLE. HRs were calculated as durvalumab with/without tremelimumab versus chemotherapy. bTMB, blood plasma tumor mutational burden; D, durvalumab; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SoC, standard of care; tTMB, tissue tumor mutational burden.

Forest plot of OS in the bTMB-high and bTMB-low subgroups by bTMB cutoff for durvalumab monotherapy versus SoC (A) and for durvalumab plus tremelimumab versus SoC (B) and PFS in the bTMB-high and bTMB-low subgroups by bTMB cutoff for durvalumab versus SoC (C) and for durvalumab plus tremelimumab versus SoC (D) in EAGLE. HRs were calculated as durvalumab with/without tremelimumab versus chemotherapy. bTMB, blood plasma tumor mutational burden; D, durvalumab; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SoC, standard of care; tTMB, tissue tumor mutational burden.